 |
Organizational profiles, sales force
deployments and competitive strategies in HIV |
|
Executive profiles of senior managers
at the top 5 oncology companies: competitive approaches and decision making styles |
|
Advantages and disadvantages of developing
drugs collaboratively with specific, NIH subsidiary institutes |
|
Levels of compliance with OIG and PhRMA
promotional guidelines by Big Pharma companies |
|
Advantages and disadvantages of operating
oncology as a separate business unit |
|
How 10 top pharmaceutical companies
organize and manage their competitive intelligence operations |
|
How 6 large, European-headquartered
pharmaceutical companies manage their Phase IV studies |
|
Attitudes and approaches of 12 major
pharmaceutical companies toward consumer database marketing |
|
Levels and mix of prelaunch, marketing
spend by each of five successful products that were fourth entries into their respective
categories |
|
Profiling essential elements in the
Rx to OTC switches of six products |
|
Assessing how five major competitors
determine respective positionings for their oral antibiotics |
|
The organization, operating principles
and shortcomings of public affairs at four major pharmaceutical companies |
|
The experiences of four pharmaceutical
manufacturers in developing oncology products collaboratively with the National Cancer
Institute |
